Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.73 |
| ▸ | JAK3 | P52333 | 16/20 | 0.73 |
| ▸ | JAK1 | P23458 | 12/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | BLK | P51451 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694572 | 1.00 | JAK2 (0.73) | JAK2JAK3JAK1ADORA2AIRAK4 | |
| SCHEMBL1693758 | 0.91 | JAK2 (0.84) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL1693019 | 0.90 | JAK2 (0.82) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL1693649 | 0.85 | JAK2 (0.81) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL14849917 | 0.84 | JAK2 (1.00) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL1694324 | 0.84 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL1694495 | 0.84 | JAK2 (1.00) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL1694331 | 0.84 | JAK2 (0.83) | JAK2JAK3JAK1ADORA2A | |
| SCHEMBL12069370 | 0.84 | JAK2 (0.83) | JAK2JAK3JAK1 | |
| SCHEMBL1694328 | 0.84 | JAK2 (0.83) | JAK2JAK3JAK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | claimed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157397-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-12-22 | — | — | WO | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.